Resistin and Cardiovascular Disease: A Review of the Current Literature Regarding Clinical and Pathological Relationships

Article ID: e290721195114 Pages: 7

  • * (Excluding Mailing and Handling)

Abstract

Serum resistin, mainly secreted by the bone marrow, monocytes, and macrophages, contributes to many processes, including endothelial dysfunction, Vascular Smooth Muscle Cell (VSMC) proliferation, and atherothrombosis demonstrating effects on the development of hypertension and Coronary Artery Disease (CAD). Previously published clinical studies have shown that plasma resistin levels are significantly associated with cardiovascular disease risk factors and adverse clinical outcomes associated with the condition. Resistin is associated with vascular smooth muscle cell dysfunction in vitro, most plausibly due to its relationship with oxidative stress in advanced atherosclerosis whereas in vivo studies have shown resistin to be associated with intimal hyperplasia. We aimed to summarize the role of resistin on cardiovascular disease (CVD), as we could not find any review focused on the role of resistin on CVD.

Keywords: Atherosclerosis, coronary artery disease, resistin, endothelial dysfunction, intimal hyperplasia, hypertension.

Graphical Abstract

[1]
Calabrò P, Cirillo P, Limongelli G, et al. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-ĸB-dependent pathway. J Vasc Res 2011; 48(1): 59-66.
[http://dx.doi.org/10.1159/000318775] [PMID: 20628259]
[2]
Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett 2002; 530(1-3): 158-62.
[http://dx.doi.org/10.1016/S0014-5793(02)03450-6] [PMID: 12387885]
[3]
Steppan CM, Brown EJ, Wright CM, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98(2): 502-6.
[http://dx.doi.org/10.1073/pnas.98.2.502] [PMID: 11209052]
[4]
Holcomb IN, Kabakoff RC, Chan B, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000; 19(15): 4046-55.
[http://dx.doi.org/10.1093/emboj/19.15.4046] [PMID: 10921885]
[5]
Gao F, Si F, Feng S, Yi Q, Liu R. Resistin enhances inflammatory cytokine production in coronary artery tissues by activating the NF-κB signaling. BioMed Res Int 2016; 2016: 3296437.
[http://dx.doi.org/10.1155/2016/3296437] [PMID: 27800490]
[6]
Menzaghi C, Marucci A, Antonucci A, et al. Suggestive evidence of a multi-cytokine resistin pathway in humans and its role on cardiovascular events in high-risk individuals. Sci Rep 2017; 7: 44337.
[http://dx.doi.org/10.1038/srep44337] [PMID: 28290549]
[7]
Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004; 255(4): 439-47.
[http://dx.doi.org/10.1111/j.1365-2796.2004.01306.x] [PMID: 15049878]
[8]
Raghuraman G, Zuniga MC, Yuan H, Zhou W. PKCε mediates resistin-induced NADPH oxidase activation and inflammation leading to smooth muscle cell dysfunction and intimal hyperplasia. Atherosclerosis 2016; 253: 29-37.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.08.015] [PMID: 27573736]
[9]
Cabrera de León A, Almeida González D, González Hernández A, et al. The association of resistin with coronary disease in the general population. J Atheroscler Thromb 2014; 21(3): 273-81.
[http://dx.doi.org/10.5551/jat.19273] [PMID: 24201007]
[10]
Kunnari A, Ukkola O, Päivänsalo M, Kesäniemi YA. High plasma resistin level is associated with enhanced highly sensitive C-reactive protein and leukocytes. J Clin Endocrinol Metab 2006; 91(7): 2755-60.
[http://dx.doi.org/10.1210/jc.2005-2115] [PMID: 16608899]
[11]
Kibar Yİ, Albayrak F, Arabul M, Dursun H, Albayrak Y, Ozturk Y. Resistin: New serum marker for predicting severity of acute pancreatitis. J Int Med Res 2016; 44(2): 328-37.
[http://dx.doi.org/10.1177/0300060515605428] [PMID: 26857860]
[12]
Niaz S, Latif J, Hussain S. Serum resistin: A possible link between inflammation, hypertension and coronary artery disease. Pak J Med Sci 2019; 35(3): 641-6.
[http://dx.doi.org/10.12669/pjms.35.3.274] [PMID: 31258568]
[13]
Zhang L, Curhan GC, Forman JP. Plasma resistin levels associate with risk for hypertension among nondiabetic women. J Am Soc Nephrol 2010; 21(7): 1185-91.
[http://dx.doi.org/10.1681/ASN.2009101053] [PMID: 20378819]
[14]
Gencer B, Auer R, de Rekeneire N, et al. Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. Atherosclerosis 2016; 245: 181-6.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.12.004] [PMID: 26724528]
[15]
Joksić J, Sopić M, Spasojević-Kalimanovska V, et al. Higher circulating resistin protein and PBMCs resistin mRNA levels are associated with increased prevalence of small dense LDL particles in coronary artery disease patients. Clin Exp Pharmacol Physiol 2016; 43(1): 22-8.
[http://dx.doi.org/10.1111/1440-1681.12503] [PMID: 26466550]
[16]
Li S, Xu RX, Zhang Y, et al. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status. J Endocrinol Invest 2015; 38(12): 1291-9.
[http://dx.doi.org/10.1007/s40618-015-0310-y] [PMID: 26003826]
[17]
Fontana A, Spadaro S, Copetti M, et al. Association between resistin levels and all-cause and cardiovascular mortality: a new study and a systematic review and meta-analysis. PLoS One 2015; 10(3): e0120419.
[http://dx.doi.org/10.1371/journal.pone.0120419] [PMID: 25793385]
[18]
Lim S, Koo BK, Cho SW, et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis 2008; 196(1): 398-404.
[http://dx.doi.org/10.1016/j.atherosclerosis.2006.11.017] [PMID: 17178123]
[19]
Kapłon-Cieślicka A, Tymińska A, Rosiak M, et al. Resistin is a prognostic factor for death in type 2 diabetes. Diabetes Metab Res Rev 2019; 35(2): e3098.
[PMID: 30447052]
[20]
Menzaghi C, Bacci S, Salvemini L, et al. Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. PLoS One 2013; 8(6): e64729.
[http://dx.doi.org/10.1371/journal.pone.0064729] [PMID: 23755138]
[21]
Solis-Cano DG, Porchia LM, Gonzalez-Mejia ME, et al. Serum resistin levels inversely associated with cardiovascular risk indices in type 2 diabetics from central Mexico. Diabetes Metab Syndr 2017; 11(Suppl. 2): S1053-7.
[http://dx.doi.org/10.1016/j.dsx.2017.07.040] [PMID: 28760596]
[22]
Zhang JZ, Gao Y, Zheng YY, et al. Increased serum resistin level is associated with coronary heart disease. Oncotarget 2017; 8(30): 50148-54.
[http://dx.doi.org/10.18632/oncotarget.15707] [PMID: 28404934]
[23]
Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005; 111(7): 932-9.
[http://dx.doi.org/10.1161/01.CIR.0000155620.10387.43] [PMID: 15710760]
[24]
Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 2004; 1(2): e45.
[http://dx.doi.org/10.1371/journal.pmed.0010045] [PMID: 15578112]
[25]
Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science 2004; 303(5661): 1195-8.
[http://dx.doi.org/10.1126/science.1092341] [PMID: 14976316]
[26]
Zheng H, Xu H, Xie N, Huang J, Fang H, Luo M. Association of serum resistin with peripheral arterial disease. Pol Arch Med Wewn 2013; 123(12): 680-5.
[http://dx.doi.org/10.20452/pamw.2011] [PMID: 24067537]
[27]
Ramirez JL, Khetani SA, Zahner GJ, et al. Serum resistin is associated with impaired endothelial function and a higher rate of adverse cardiac events in patients with peripheral artery disease. J Vasc Surg 2019; 69(2): 497-506.
[http://dx.doi.org/10.1016/j.jvs.2018.05.251] [PMID: 30292618]
[28]
Jiang CY, Wang W, Tang JX, Yuan ZR. The adipocytokine resistin stimulates the production of proinflammatory cytokines TNF-α and IL-6 in pancreatic acinar cells via NF-κB activation. J Endocrinol Invest 2013; 36(11): 986-92.
[PMID: 23765438]
[29]
Park HK, Kwak MK, Kim HJ, Ahima RS. Linking resistin, inflammation, and cardiometabolic diseases. Korean J Intern Med (Korean Assoc Intern Med) 2017; 32(2): 239-47.
[http://dx.doi.org/10.3904/kjim.2016.229] [PMID: 28192887]
[30]
Wu D, Shen YH, Russell L, Coselli JS, LeMaire SA. Molecular mechanisms of thoracic aortic dissection. J Surg Res 2013; 184(2): 907-24.
[http://dx.doi.org/10.1016/j.jss.2013.06.007] [PMID: 23856125]
[31]
Barbetseas J, Alexopoulos N, Brili S, et al. Atherosclerosis of the aorta in patients with acute thoracic aortic dissection. Circ J 2008; 72(11): 1773-6.
[http://dx.doi.org/10.1253/circj.CJ-08-0433] [PMID: 18832775]
[32]
Liu X, Zheng X, Su X, Tian W, Hu Y, Zhang Z. Plasma resistin levels in patients with acute aortic dissection: a propensity score- matched observational case-control study. Med Sci Monit 2018; 24: 6431-7.
[http://dx.doi.org/10.12659/MSM.909469] [PMID: 30212440]
[33]
Haas B, Mayer P, Jennissen K, et al. Protein kinase G controls brown fat cell differentiation and mitochondrial biogenesis. Sci Signal 2009; 2(99): ra78.
[http://dx.doi.org/10.1126/scisignal.2000511] [PMID: 19952371]
[34]
Jennissen K, Siegel F, Liebig-Gonglach M, et al. A VASP-Rac- soluble guanylyl cyclase pathway controls cGMP production in adipocytes. Sci Signal 2012; 5(239): ra62.
[http://dx.doi.org/10.1126/scisignal.2002867] [PMID: 22932701]
[35]
Wang J, Jia Y, Wang L, et al. Vasodilator-stimulated phosphoprotein: regulators of adipokines resistin and phenotype conversion of epicardial adipocytes. Med Sci Monit 2018; 24: 6010-20.
[http://dx.doi.org/10.12659/MSM.908111] [PMID: 30156215]
[36]
Takeishi Y, Niizeki T, Arimoto T, et al. Serum resistin is associated with high risk in patients with congestive heart failure-a novel link between metabolic signals and heart failure. Circ J 2007; 71(4): 460-4.
[http://dx.doi.org/10.1253/circj.71.460] [PMID: 17384443]
[37]
Baldasseroni S, Mannucci E, Di Serio C, et al. Resistin level in coronary artery disease and heart failure: the central role of kidney function. J Cardiovasc Med (Hagerstown) 2013; 14(2): 150-7.
[http://dx.doi.org/10.2459/JCM.0b013e32834eec93] [PMID: 22240747]
[38]
Turgay Yıldırım Ö, Yıldırır A, Sade LE, et al. Is there a relationship between resistin levels and left ventricular end-diastolic pressure? Anatol J Cardiol 2018; 19(4): 267-72.
[http://dx.doi.org/10.14744/AnatolJCardiol.2018.66181] [PMID: 29615544]
[39]
Palombo C, Kozakova M. Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indications. Vascul Pharmacol 2016; 77: 1-7.
[http://dx.doi.org/10.1016/j.vph.2015.11.083] [PMID: 26643779]
[40]
Norman G, Norton GR, Gomes M, et al. Circulating resistin concentrations are independently associated with aortic pulse wave velocity in a community sample. J Hypertens 2016; 34(2): 274-81.
[http://dx.doi.org/10.1097/HJH.0000000000000792] [PMID: 26867055]
[41]
Wang JH, Lee CJ, Yang CF, Chen YC, Hsu BG. Serum resistin as an independent marker of aortic stiffness in patients with coronary artery disease. PLoS One 2017; 12(8): e0183123.
[http://dx.doi.org/10.1371/journal.pone.0183123] [PMID: 28806778]
[42]
Munjas J, Sopić M, Bogavac-Stanojević N, et al. Serum resistin, adenylate cyclase-associated protein 1 gene expression, and carotid intima-media thickness in patients with end-stage renal disease and healthy controls. Cardiorenal Med 2020; 10(1): 51-60.
[http://dx.doi.org/10.1159/000503416] [PMID: 31722350]
[43]
Bonito B, Silva AP, Rato F, Santos N, Neves PL. Resistin as a predictor of cardiovascular hospital admissions and renal deterioration in diabetic patients with chronic kidney disease. J Diabetes Complications 2019; 33(11): 107422.
[http://dx.doi.org/10.1016/j.jdiacomp.2019.107422] [PMID: 31484628]
[44]
Baye E, Ukropec J, de Courten MPJ, et al. Carnosine supplementation improves serum resistin concentrations in overweight or obese otherwise healthy adults: a pilot randomized trial. Nutrients 2018; 10(9): 1258.
[http://dx.doi.org/10.3390/nu10091258] [PMID: 30205427]